Any adverse effects (including constipation, nausea, vomiting, heartburn or diarrhoea, as measured by trialists) · general population older than 2 years of age (including pregnant women), in Kenya and Mexico
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher quality of life: number of participants with clinically significant… compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher improvement in symptoms: number of participants with clinically… compared with placebo (high certainty).
1 finding from 1 review
Lung function · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Threshold · asymptomatic newborns at the time of pulse oximetry screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
95% (less than or less than or equal to) · asymptomatic newborns at the time of pulse oximetry screening
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsd · patients with chronic obstructive pulmonary disease
1 finding from 1 review
CAT score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · patients with chronic obstructive pulmonary disease
2 findings from 1 review
Dyspnoea ‐ change in mMRC Scale 0 to 4. Lower is better and 1 unit is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsf · patients with chronic obstructive pulmonary disease
1 finding from 1 review
General health‐related quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life (mental) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review